Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity

Journal of Controlled Release

Volumn 142, Issue 2, 2010, Pages 187-195

  Kim, Yeu Chun ^a   Quan, Fu Shi ^b   Compans, Richard W ^b   Kang, Sang Moo ^b   Prausnitz, Mark R ^a  

^a Georgia Institute of Technology   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inactivated virus vacccine; Influenza virus; Microneedle; Trehalose

Indexed keywords

ACTIVITY LOSS; CARBOXY METHYLCELLULOSE; COATING FORMULATIONS; DIP COATING; DYNAMIC LIGHT SCATTERING MEASUREMENT; EXPERIMENTAL FACTORS; IMMUNOGENICITY; INACTIVATED VIRUS; INFLUENZA VACCINES; INFLUENZA VIRUS; INTRAMUSCULAR INJECTIONS; MECHANISTIC PATHWAYS; MICRONEEDLES; PARTICLE AGGREGATION; THERMAL STABILITY;

AGGLOMERATION; ANTIGENS; COATINGS; STABILIZATION; VACCINES; VIRUSES;

NEEDLES;

CARBOXYMETHYLCELLULOSE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; TREHALOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; FEMALE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MOUSE; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE; THERMOSTABILITY; VIRUS PARTICLE; VISCOSITY;

ANIMALS; ANTIBODY FORMATION; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZAVIRUS B; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; TEMPERATURE; TREHALOSE;

EID: 76749169710     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.10.013     Document Type: Article

References (50)

1. ACIP. Prevention and control of influenza, recommendations of the Advisory Committee on Immunization Practices. Morb. Mortal. Wkly. Rep. 2008, 57:1-60. Centers for Disease Control and Prevention.
2. Thompson W.W., Shay D.K., Weintraub E., Brammer I., Bridges C.B., Cox N.J., Fukuda K. Influenza-associated hospitalizations in the United States. J. Am. Med. Assoc. 2004, 292:1333-1340.
3. Palese P. Influenza: old and new threats. Nat. Med. 2004, 10:S82-S87.
4. Hoelscher M., Gangappa S., Zhong W.M., Jayashankar L., Sambhara S. Vaccines against epidemic and pandemic influenza. Expert Opin. Drug Deliv. 2008, 5:1139-1157.
5. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., Howe B.J., Dubin G. Serum antibody responses after intradermal vaccination against influenza. New Engl. J. Med. 2004, 351:2286-2294.
6. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. New Engl. J. Med. 2004, 351:2295-2301.
7. Holland D., Booy R., De Looze F., Eizenberg P., McDonald J., Karrasch J., McKeirnan M., Salem H., Mills G., Reid J., Weber F., Saville M. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: A randomized controlled trial. J. Infect. Dis. 2008, 198:650-658.
8. Howard A., Mercer P., Nataraj H.C., Kang B.C. Bevel-down superior to bevel-up in intradermal skin testing. Ann. Allergy, Asthma, & Immun. 1997, 78:594-596.
9. Laurent P.E., Bonnet S., Alchas P., Regolini P., Mikszta J.A., Pettis R., Harvey N.G. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007, 25:8833-8842.
10. Glenn G.M., Flyer D.C., Ellingsworth L.R., Frech S.A., Frerichs D.M., Seid R.C., Yu J. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev. Vaccines 2007, 6:809-819.
11. Babiuk S., Baca-Estrada M., Babiuk L.A., Ewen C., Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J. Control. Release 2000, 66:199-214.
12. Celluzzi C.M., Falo L.D. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J. Invest. Dermatol. 1997, 108:716-720.
13. Leroux-Roels I., Vets E., Freese R., Seiberling M., Weber F., Salamand C., Leroux-Roels G. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 2008, 26:6614-6619.
14. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27:454-459.
15. Mikszta J.A., Alarcon J.B., Brittingham J.M., Sutter D.E., Pettis R.J., Harvey N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 2002, 8:415-419.
16. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines - protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11478-11482.
17. Ren S., Li M, Smith J.M, DeTolla L.J, Furth P.A. Low-volume jet injection for intradermal immunization in rabbits. BMC Biotechnol. 2002, 2:10.
18. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M.C., Leung L., Otten G.R., Thudium K., Selby M.J., Ulmer J.B. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 2000, 164:4635-4640.
19. Bramson J., Dayball K., Evelegh C., Wan Y.H., Page D., Smith A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther. 2003, 10:251-260.
20. Garg S., Hoetscher M., Belser J.A., Wang C., Jayashankar L., Guo Z., Durland R.H., Katz J.M., Sambhara S. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice. Clin. Vaccine Immunol. 2007, 14:926-928.
21. Hirschberg H.J.H.B., de Wijdeven G.G.P.V., Kelder A.B., van den Dobbelsteen G.P.J.M., Kerstena G.F.A. Bioneedles (TM) as vaccine carriers. Vaccine 2008, 26:2389-2397.
22. Eriksson E., Yao F., Svensjo T., Winkler T., Slama J., Macklin M.D., Andree C., McGregor M., Hinshaw V., Swain W.F. In vivo gene transfer to skin and wound by microseeding. J. Surg. Res. 1998, 78:85-91.
23. Prausnitz M.R., Mikszta J.A., Cormier M., Andrianov A.K. Microneedle-based vaccines. Current Topics in Microbiology and Immunology: Vaccines for Pandemic Influenza 2009, Springer-Verlag, Berlin/Heidelberg. R.W. Compans, W.A. Orenstein (Eds.).
24. Matriano J.A., Cormier M., Johnson J., Young W.A., Buttery M., Nyam K., Daddona P.E. Macroflux® microprojection array patch technology: A new and efficient approach for intracutaneous immunization. Pharm. Res. 2002, 19:63-70.
25. Widera G., Johnson J., Kim L., Libiran L., Nyam K., Daddona P.E., Cormier M. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006, 24:1653-1664.
26. Koutsonanos D.G., Martin M.d.P., Zarnitsyn V.G., Sullivan S.P., Compans R.W., Prausnitz M.R., Skountzou I. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 2009, 4(3):e4773.
27. Zhu Q.Y., Zarnitsyn V.G., Ye L., Wen Z., Gao Y., Pan L., Skountzou I., Gill H.S., Prausnitz M.R., Yang Y., Compans R.W. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7968-7973.
28. Gill H.S., Prausnitz M.R. Coated microneedles for transdermal delivery. J. Control. Release 2007, 117:227-237.
29. Leslie S.B., Israeli E., Lighthart B., Crowe J.H., Crowe L.M. Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying. Appl. Environ. Microbiol. 1995, 61:3592-3597.
30. Leslie S.B., Teter S.A., Crowe L.M., Crowe J.H. Trehalose lowers membrane phase-transitions in dry yeast-cells. Biochim. Biophys. Acta 1994, 1192:7-13.
31. Bieganski R.M., Fowler A., Morgan J.R., Toner M. Stabilization of active recombinant retroviruses in an amorphous dry state with trehalose. Biotechnol. Prog. 1998, 14:615-620.
32. Crowe J.H., Crowe L.M., Carpenter J.F., Wistrom C.A. Stabilization of dry phospholipid-bilayers and proteins by sugars. Biochem. J. 1987, 242:1-10.
33. Sun W.Q., Leopold A.C., Crowe L.M., Crowe J.H. Stability of dry liposomes in sugar glasses. Biophys. J. 1996, 70:1769-1776.
34. Quan F.S., Compans R.W., Nguyen H.H., Kang S.M. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 2008, 82:1350-1359.
35. Connolly S.A., Lamb R.A. Paramyxovirus fusion: real-time measurement of parainfluenza virus 5 virus-cell fusion. Virology 2006, 355:203-212.
36. Ludwig K., Korte T., Herrmann A. Analysis of delay times of hemagglutinin-mediated fusion between influenza-virus and cell-membranes. Eur. Biophys. J. 1995, 24:55-64.
37. Skountzou I., Quan F.S., Jacob J., Compans R.W., Kang S.M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 2006, 24:6110-6119.
38. Gill H.S., Denson D.D., Burris B.A., Prausnitz M.R. Effect of microneedle design on pain in human volunteers. Clin. J. Pain 2008, 24:585-594.
39. Vyas G.N., Shulman N.R. Hemagglutination assay for antigen and antibody associated with viral hepatitis. Science 1970, 170:332-333.
40. Amorij J.P., Huckriede A., Wischut J., Frifflink H.W., Hinrichs W.L.J. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 2008, 25:1256-1273.
41. Hobson D., Curry R.L., Beare A.S., Wardgard A The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 1972, 70:767-777.
42. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004, 59:1-15.
43. Nicholson K.G., Wood J.M., Zambon M. Influenza. Lancet 2003, 362:1733-1745.
44. de Jonge J., Amorij J.P., Hinrichs W.L.J., Wiischuta J., Huckriedea A., Frijlinkb H.W. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur. J. Pharm. Sci. 2007, 32:33-44.
45. Allison S.D., Molina M.D.C., Anchordoquy T.J. Stabilization of lipid/DNA complexes during the freezing step of the lyophilization process: the particle isolation hypothesis. Biochim. Biophys. Acta 2000, 1468:127-138.
46. Amorij J.P., Meulenaar J., Hinrichs W.L.J., Stegmann T., Huckriede A., Coenen F., Frijlink H.W. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007, 25:6447-6457.
47. Carpenter J.F., Crowe J.H. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 1989, 28:3916-3922.
48. Carpenter J.F., Martin B., Crowe L.M., Crowe J.H. Stabilization of phosphofructokinase during air-drying with sugars and sugar transition-metal mixtures. Cryobiology 1987, 24:455-464.
49. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999, 258:1-20.
50. Azzi L., El-Alfy M., Martel C., Labrie F. Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. J. Invest. Dermatol. 2005, 124:22-27.